AD

Award Number: W81XWH-09-1-0129

TITLE: Targeting Ovarian Carcinoma Stem Cells

PRINCIPAL INVESTIGATOR: Richard Jones, M.D.

CONTRACTING ORGANIZATION: Johns Hopkins University Baltimore, MD 21205

REPORT DATE: May 2012

TYPE OF REPORT: Ü^çã^å/kinal

# PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

					Form Approved		
					OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing							
this burden to Department of E 4302. Respondents should be	efense, Washington Headquart	ers Services, Directorate for Info	rmation Operations and Reports	(0704-0188), 1215 Jeffer for failing to comply with	son Davis Highway, Suite 1204, Arlington, VA 22202- a collection of information if it does not display a currently		
valid OMB control number. PL	EASE DO NOT RETURN YOU	R FORM TO THE ABOVE ADD	RESS.				
1. REPORT DATE		2. REPORT TYPE		3. D.	ATES COVERED		
May 2012		U^ça^a/a/Final		1 M	ay 2009 – 30 April 2012		
4. IIILE AND SUBIII	LE			Sa. C			
Terretien	0	N - 11 -		Eb. (			
Targeting Ovarian	Carcinoma Stem C	Jelis		50. V \//8	1X\//H_00_1_0120		
				50.5			
				5C. I	ROGRAM ELEMENT NOMBER		
				54			
0. AUTHOR(3)				50.1	ROJECT NOMBER		
Dishard Ispas M				50.7			
Richard Jones, M.	D.			Je.	ASK NOMBER		
				5f V			
E-Mail: rijones@hmi.e	du			51. 4	VORR ONT NOMBER		
				0 D			
7. PERFORMING ORG	JANIZATION NAME(3)	AND ADDRESS(ES)		0. P	UMBER		
Johns Honkins I In	iversity						
Baltimore MD 212	205						
	.00						
			C/EC)	10.6			
9. SPONSORING / MC	I Desearch and Ma	tarial Command	5(E3)	10. 3	BPONSOR/MONITOR S ACRONTM(S)		
Eart Datrick Mary	and 21702 5012						
FULL Dellick, Mary	anu 21702-5012			11.0			
				11.	SPONSOR/MONITOR S REPORT		
				r	NUMBER(5)		
12. DISTRIBUTION / A	VAILABILITY STATEN	NENT					
Approved for Public Release; Distribution Unlimited							
13. SUPPLEMENTAR	Y NOTES						
13. SUPPLEMENTAR	YNOTES						
13. SUPPLEMENTAR	YNOTES						
13. SUPPLEMENTAR	YNOTES						
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car	Y NOTES	m rare, primitive self-ren	ewing cancer cells, that a	are biologically dist	inct from their more numerous differentiated		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing	Y NOTES cers appear to arise fro the malignancy. Althou	m rare, primitive self-ren gh the clinical significance	ewing cancer cells, that a	are biologically dist ells (CSC) has bee	inct from their more numerous differentiated en uncertain, our data suggest that they are		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o	Y NOTES cers appear to arise fro the malignancy. Althou f the relapses that follow	m rare, primitive self-ren gh the clinical significanc v anticancer therapy. Ob	ewing cancer cells, that a se of these cancer stem c jective/Hypothesis: We h	are biologically dist ells (CSC) has been ypothesize that the	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare resistant CSC Th	Y NOTES cers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of the	m rare, primitive self-ren gh the clinical significanc v anticancer therapy. Ob against the differentiated	ewing cancer cells, that a ce of these cancer stem o jective/Hypothesis: We h d cancer cells making up	are biologically dist ells (CSC) has be ypothesize that the the bulk of the tur	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent welon novel therapies that target these		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell	Y NOTES cers appear to arise fro the malignancy. Althou f the relapses that follov erapeutic effectiveness e overall objectives of th characteristics and path	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer	ewing cancer cells, that a ce of these cancer stem o jective/Hypothesis: We h d cancer cells making up ify and characterize ovari ts of both the characterize	are biologically dist rells (CSC) has bea ypothesize that the the bulk of the tur an CSC, and to de ration and therape	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify.		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz	Y NOTES cers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of tt characteristics and patt ie ovarian CSC, and 2)	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident tways will be key elemer Develop clinical approac	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari ts of both the characteriz hes for eliminating ovaria	are biologically dist cells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de cation and therape n CSC. Study De	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN	Y NOTES cers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of th characteristics and path the ovarian CSC, and 2) AR) that mimics the hur	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident nways will be key elemer Develop clinical approac nan disease, strategies v	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari hts of both the characteriz hes for eliminating ovaria will be developed to isola	are biologically dist bells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape n CSC. Study De te and characterize	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian for, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us therefore the studies us	Y NOTES A cers appear to arise fro the malignancy. Althour f the relapses that follow erapeutic effectiveness e overall objectives of the characteristics and path the ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell a certain certain the certain certain certain certain the certain certa	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident tways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari hts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape n CSC. Study De- te and characterize noma. Our prelimi	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian tor, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan	Y NOTES Accers appear to arise fro the malignancy. Althou, f the relapses that follow erapeutic effectiveness e overall objectives of th characteristics and path :e ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FN/ (data demonstrate hum	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur an ovarian cancer cell li	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari nts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci mors in rats. These cells pes contain a parallel A1	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize noma. Our prelimi highly CD24, CD4	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian tor, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to nary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan will also be initially test	Y NOTES Accers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of th characteristics and path :e ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FN/ r data demonstrate hum ad in the rat model and	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines: those v	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari hts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci nors in rats. These cells nes contain a parallel ALI with activity in these mod	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell els will be evaluate	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many of carcinoma represent the rare, resistant CSC. The cells. Shared stem cell isolate, and characterized ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th	Y NOTES A cers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of th characteristics and patt characteristics and patt (characteristics and p	m rare, primitive self-ren gh the clinical significanc v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur an ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari hts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci mors in rats. These cells nes contain a parallel ALI with activity in these modo ous implications for the d	are biologically dist iells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de cation and therape in CSC. Study De the and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to nary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan will also be initially test specimens. Impact: Th would explain the trans	Y NOTES Incers appear to arise fro the malignancy. Althou f the relapses that follow erapeutic effectiveness e overall objectives of the characteristics and path is overall objectives of the isomethic overall objectives of the characteristics and path isomethic overall objectives of the characteristics and path isomethic overall objectives of the characteristics overall objectives overall isomethic overall objectives of the overall objectives of the isomethic overall objectives of the overall objectives of the isomethic overall objectives of the overall objectives overall objectives overall objectives overall overall overall objectives overall over	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur an ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari the of both the characteriz hes for eliminating ovaria will be developed to isola nary human ovarian carci nors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom	are biologically dist tells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize and characterize te and cha	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to nary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many of carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan will also be initially test specimens. Impact: Th would explain the trans facilitate the development	Y NOTES Incers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness e overall objectives of th characteristics and path the ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FNA data demonstrate hum ed in the rat model and a potential existence of ient remissions that cha ent of novel treatment a	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari ts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci nors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom	are biologically dist cells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de cation and therape the and characterize noma. Our prelimin highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan will also be initially test specimens. Impact: Th would explain the trans facilitate the development	Y NOTES Incers appear to arise fro the malignancy. Althou f the relapses that follow ierapeutic effectiveness re overall objectives of th characteristics and path is ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FN/ / data demonstrate hum ed in the rat model and e potential existence of ient remissions that cha ent of novel treatment a	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari thes for eliminating ovaria will be developed to isolar nary human ovarian carci mors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de zation and therape n CSC. Study De te and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th would explain the trans facilitate the development 15. SUBJECT TERMS Ovarian Carcinom	Y NOTES Incers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness le overall objectives of characteristics and patt is ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FN/ / data demonstrate hum ed in the rat model and e potential existence of ient remissions that char ant of novel treatment ap a, Cancer Stem Ce	m rare, primitive self-ren gh the clinical significance v anticancer therapy. Ob against the differentiated hese studies are to ident tways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur an ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari- nts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci- nors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom	are biologically dist sells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize noma. Our prelimin highly CD24, CD4 DH-expressing cell evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian tor, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminan will also be initially test specimens. Impact: Th would explain the trans facilitate the developme 15. SUBJECT TERMS Ovarian Carcinom	Y NOTES Accers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness le overall objectives of the characteristics and path e ovarian CSC, and 2) AR) that mimics the hum sing human ovarian cell ) expression marks FN/ / data demonstrate hum ed in the rat model and e potential existence of ient remissions that char ent of novel treatment and a, Cancer Stem Ce	m rare, primitive self-ren gh the clinical significance v anticancer therapy. Ob against the differentiated hese studies are to ident hways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari nts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci mors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize noma. Our prelimin highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th would explain the trans facilitate the developme 15. SUBJECT TERMS Ovarian Carcinom 16. SECURITY CLASS	Y NOTES Icers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness le overall objectives of the characteristics and path e ovarian CSC, and 2) I AR) that mimics the hurn sing human ovarian cell ) expression marks FN/4 v data demonstrate hum ed in the rat model and e potential existence of ient remissions that char ent of novel treatment approximation a, Cancer Stem Ce IFICATION OF:	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident tways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovari nts of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carci nors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom drogenase	are biologically dist ells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also <b>19a. NAME OF RESPONSIBLE PERSON</b>		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th would explain the trans facilitate the developmed 15. SUBJECT TERMS Ovarian Carcinom 16. SECURITY CLASS	Y NOTES Accers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness le overall objectives of the characteristics and path characteristics and path characteristics and path characteristics and path characteristics and path characteristics and path (characteristics and path characteristics and path (characteristics a	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovariants of both the characterize hes for eliminating ovaria will be developed to isolar nary human ovarian carci nors in rats. These cells nes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom drogenase	are biologically dist tells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de cation and therape in CSC. Study De the and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also <b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many of carcinoma represent the rare, resistant CSC. The cells. Shared stem cell isolate, and characterized ovarian carcinoma (FN) guide similar studies us dehydrogenase (ALDH) tumor cells. Preliminary will also be initially test specimens. Impact: The would explain the transfacilitate the development 15. SUBJECT TERMS Ovarian Carcinoment 16. SECURITY CLASS a. REPORT	Y NOTES iccers appear to arise fro the malignancy. Althou f the relapses that follow ierapeutic effectiveness ie overall objectives of ti characteristics and patt the overall objectives of ti characteristics and patt the overall objective of the characteristics and patt the overall objectives of ti characteristics and patt the overall objective of the ing human ovarian cell ) expression marks FN// (data demonstrate hum ed in the rat model and e potential existence of ient remissions that char ant of novel treatment applied a, Cancer Stem Ce ilFICATION OF: b. ABSTRACT	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches.	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovariants of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carcinors in rats. These cells ness contain a parallel ALI with activity in these modo ous implications for the d ents for ovarian carcinom drogenase	are biologically dist rells (CSC) has be ypothesize that the the bulk of the tur an CSC, and to de ration and therape n CSC. Study De te and characterize noma. Our prelimi highly CD24, CD4 DH-expressing cell evelopment of nov a. Isolation and ch	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent velop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also <b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC <b>19b. TELEPHONE NUMBER</b> (include area		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th would explain the trans facilitate the development 15. SUBJECT TERMS Ovarian Carcinom 16. SECURITY CLASS a. REPORT U	Y NOTES Accers appear to arise fro the malignancy. Althou f the relapses that follow lerapeutic effectiveness le overall objectives of ti characteristics and patt ze ovarian CSC, and 2) AR) that mimics the hur sing human ovarian cell ) expression marks FN// / data demonstrate hum ed in the rat model and e potential existence of ient remissions that char ant of novel treatment approximation a, Cancer Stem Ce IFICATION OF: b. ABSTRACT U	m rare, primitive self-ren gh the clinical significand v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur an ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches. ells, Aldehyde Dehyd c. THIS PAGE U	ewing cancer cells, that a ce of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovaria thes of both the characteriz hes for eliminating ovaria will be developed to isolar nary human ovarian carcinors in rats. These cells ness contain a parallel ALL with activity in these mode ous implications for the d ents for ovarian carcinom drogenase 17. LIMITATION OF ABSTRACT UU	are biologically dist rells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape n CSC. Study De- te and characterize and characterize te and characterize anoma. Our prelimin highly CD24, CD4 DH-expressing cell evelopment of nov a. Isolation and ch <b>18. NUMBER</b> <b>OF PAGES</b> Ì	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also <b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC <b>19b. TELEPHONE NUMBER</b> (include area code)		
13. SUPPLEMENTAR 14. ABSTRACT Background: Many car progeny characterizing responsible for many o carcinoma represent th rare, resistant CSC. Th cells. Shared stem cell isolate, and characteriz ovarian carcinoma (FN guide similar studies us dehydrogenase (ALDH tumor cells. Preliminary will also be initially test specimens. Impact: Th would explain the trans facilitate the development 15. SUBJECT TERMS Ovarian Carcinom 16. SECURITY CLASS a. REPORT U	Y NOTES Incers appear to arise fro the malignancy. Althou f the relapses that follow ierapeutic effectiveness ie overall objectives of the characteristics and path re ovarian CSC, and 2) AR) that mimics the hur e ovarian cSC, and 2) ( AR) tha	m rare, primitive self-ren gh the clinical significano v anticancer therapy. Ob against the differentiated hese studies are to ident ways will be key elemer Develop clinical approac nan disease, strategies v lines, and ultimately prin AR cells which initiate tur ian ovarian cancer cell lin human cell lines; those v ovarian CSC has enorm aracterize current treatme pproaches. ells, Aldehyde Dehyde c. THIS PAGE U	ewing cancer cells, that a ze of these cancer stem of jective/Hypothesis: We h d cancer cells making up ify and characterize ovaria thes for eliminating ovaria will be developed to isolar nary human ovarian carci mors in rats. These cells hes contain a parallel ALI with activity in these mode ous implications for the d ents for ovarian carcinom drogenase 17. LIMITATION OF ABSTRACT	are biologically dist bells (CSC) has been ypothesize that the the bulk of the turn an CSC, and to de ration and therape in CSC. Study De- te and characterize and characterize te and characterize anoma. Our prelimin highly CD24, CD4 DH-expressing cell els will be evaluate evelopment of nov a. Isolation and ch <b>18. NUMBER</b> <b>OF PAGES</b> Ì	inct from their more numerous differentiated en uncertain, our data suggest that they are e dramatic initial response rates in ovarian ior, while the high rate of relapses represent evelop novel therapies that target these utic investigations. Specific Aims: 1) Identify, sign:. Using a spontaneously developing rat e ovarian CSC. These results will be used to hary data show that aldehyde 4 and CD47 when compared to the bulk population. Potential therapeutic strategies d against ovarian CSC from clinical el therapies for this disease. In particular, it aracterization of these cells will also <b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC <b>19b. TELEPHONE NUMBER</b> (include area code)		

# **Table of Contents**

<u>_Pa</u>	<u>age</u>
ntroduction4	
3ody4-8	8
دey Research Accomplishments8	3
Reportable Outcomes8	}
Personnel8	}
Sonclusion	В
Appendices	one

# Introduction

Recent data suggest that many cancers arise from, and are maintained by, rare selfrenewing cells that are biologically distinct from the more numerous differentiated cells that make up the bulk of the tumor. Although the clinical significance of these so-called cancer stem cells (CSCs) has been uncertain, our group and others have hypothesized that they are responsible for many of the relapses that follow anticancer therapy. Importantly, recent data in both hematologic malignancies and solid tumors from our group and others now for the first time strongly suggest that rare CSC populations are in fact relatively resistant when compared to the bulk tumor cells and responsible for relapse. Minimal residual disease (MRD), the cancer cells remaining during treatment-induced remissions, are enriched for cells with a CSC phenotype. and the presence or absence of these cells correlates with progression-free survival. Ovarian carcinoma is one of the most responsive solid tumors, with the majority of affected women now achieving complete remissions. Unfortunately, most affected women eventually relapse and die of the disease. We hypothesize that the initial clinical responses in ovarian carcinoma represent therapeutic effectiveness against differentiated cancer cells making up the bulk of the tumor, while the high rate of relapses represents rare, biologically distinct CSCs resistant to the therapies effective against the tumor bulk. The limited understanding about the phenotype of normal ovarian epithelial stem cells is an obstacle to identifying ovarian CSCs, if they exist. However, several characteristics that appear to be shared by normal stem cells from many tissues, such high expression of aldehyde dehydrogenase (ALDH) and the Hoechst side population (SP) phenotype, may serve as markers for CSCs from many malignancies. In particular, we have found that high expression of ALDH is highly expressed by, and can be used to isolate, normal stem cells and CSC from all the tissues that we have studied including, in preliminary data, ovarian CSCs. The overall objectives of these studies are to identify and characterize ovarian CSCs, and to develop novel therapies that target these cells. Shared stem cell characteristics and pathways will be key elements of both the characterization and therapeutic investigations. Combining stem cell biology expertise with expertise in gynecologic oncology/ovarian carcinoma and in animal models of cancer this proposal will: 1) Identify, isolate, and characterize ovarian CSCs, and 2) develop clinically applicable approaches for eliminating ovarian CSCs.

# Body

We have fully characterized the spontaneous rat ovarian carcinoma that is being used to model our characterization and treatment studies (Sharrow *et al J Ovarian Res.* 3:9, 2010,). The tumor, designated FNAR, could be serially transplanted into Lewis rats and propagated as a cell line *in vitro*, maintaining the properties of the original tumor. The FNAR cells displayed striking morphologic similarities to human ovarian carcinoma, resembling the endometrioid carcinoma subtype of surface epithelial neoplasms. The cells expressed estrogen receptor alpha, progesterone receptor, androgen receptor, her-2/neu, epithelial cell adhesion molecule, CA125, and nuclear beta-catenin. A gene expression profile showed upregulation of a number of genes that are also upregulated in human ovarian carcinoma. Thus, this reliable model of ovarian carcinoma should be helpful in better understanding the biology of the disease as well as the development of novel treatment strategies.

Studies into identifying and characterizing CSCs from hematologic malignancies have been greatly facilitated by a comprehensive understanding of cell surface antigen expression throughout lymphohematopoietic differentiation. In contrast, little is known about the cell surface phenotype associated with the growth and development of most non-lymphohematopoietic tissues. Thus, we have been studying the ability of the pan-stem cell marker ALDH1 to identify ovarian CSCs in this rat model, with the intent to use information in this model to interrogate human ovarian cancer. Preliminary studies showed that 2-4% of the FNAR cells express high levels of ALDH, and these cells were responsible for the producing the tumor growth upon intraperitoneal (IP) injection. Conversely, the ALDH<sup>low</sup> (>95% of the total cells) produced transient abdominal swelling and malignant ascites. However, after several passages of the line *in vitro*, the ALDH<sup>high</sup> population disappeared (Figure 1A). After studying several culture





Figure 1A. The majority of FNAR cells cultured in standard medium do not express ALDH (DEAB is control for Aldefluor).

**Figure 1B.** The majority of FNAR cells cultured in stem cell KnockOut medium express high ALDH (DEAB is control for Aldefluor).

conditions, it became clear that serum led to terminal differentiation and loss of the ALDH<sup>high</sup> subpopulation. After studying several different culture techniques, we found that upon transferring the cell line to a serum-free culture medium developed for growing undifferentiated embryonic stem cells (KnockOut SR, Invitrogen) the ALDH<sup>high</sup> population not only reappeared, but after several passages represented the predominant population in the cell line (Figure 1B). Preliminary data shows that the ALDH<sup>high</sup> cells maintained in KnockOut medium are phenotypically identical to the ALDH<sup>high</sup> cells in the early FNAR passages, while the cells maintained in standard medium are phenotypically identical to the bulk FNAR cells in the early passages. That is, both populations express most ovarian cancer markers, including Her2/neu and EPCAM. However, in addition to ALDH, the FNAR ALDH<sup>high</sup> cells (putative CSCs) expressed the stem cell markers CD24, CD44, and CD117 not expressed by the ALDH<sup>low</sup> cells. Moreover, the ALDH<sup>high</sup> FNAR cells do not appear to express any of the sex hormone receptors (ER, PR, or AR) expressed by the ALDH<sup>low</sup> cells.

Similar studies have begun on human ovarian carcinoma cell lines. The wellcharacterized human ovarian carcinoma cell line SKOV3 contained essentially no ALDH<sup>high</sup> cells after staining with Aldefluor even in KnockOut medium, similar to the FNAR cells in standard medium (Figure 2A). However, SKOV3 cells made resistant to taxol by our colleague Dr. Le-



Figure 2A. SKOV-3 ovarian CA cells cultured in stem cell KO medium express no ALDH (DEAB is control for Aldefluor).



Figure 2B. Nearly half of taxol-resistant SKOV-3 ovarian CA cells cultured in stem cell KO medium express high ALDH (DEAB is control for Aldefluor).

Ming Shih in Johns Hopkins department of Pathology contained a very high number (nearly 50%) of ALDH<sup>high</sup> cells, similar to the FNAR cells in KnockOut medium (Figure 2B).

Now that we have developed stable populations of the bulk tumor and ALDH<sup>high</sup> subpopulations for both the rat FNAR and human SCOV3 cell lines, we have again begun completing the studies characterizing them. The preliminary cell surface antigen expression results described above suggest the ALDH<sup>high</sup> cells from both the rat and human ovarian carcinoma cells have stem cell features phenotypically. The FNAR ALDH<sup>high</sup> cells when sorted into 100 cell wells, completely recapitulate the heterogeneity of the cell line grown in knock-our medium (Figure 1B), while the ALDH<sup>low</sup> cells only generate ALDH<sup>low</sup> cells cells (Figure 1A). The ALDH<sup>low</sup> cells grow adherently and have a doubling time of 18 hours, while the ALDH<sup>high</sup> cells grow both attached and in suspension and have a doubling time of 72 hours. The taxol resistant ALDH<sup>high</sup> SKOV3 cells similarly had a much longer doubling time that the ALDH<sup>low</sup> SKOV3 cells.

It has been assumed that CSCs are relatively resistant to drugs, at least in part the result of stem cell characteristics shared with normal stem cells. We studied the drug sensitivity of the ALDH<sup>high</sup> FNAR cells and the ALDH<sup>low</sup> to three of the most commonly used drugs in ovarian cancer, all with different mechanisms of action and resistance: paclitaxel, carboplatin, and gemcitabine. The ALDH<sup>high</sup> cells were relatively resistant to all 3 drugs (Figure 3A and B, data

not shown for gemcitabine). Similarly, the ALDH<sup>high</sup> SKOV3 were also relatively resistant to all three drugs (Figure 4). These data demonstrate that the putative CSCs from both the rat ovarian carcinoma and the



**Fig 3. Relative drug sensitivity of ALDH**<sup>high</sup> (red line) and ALDH<sup>low</sup> (blue line) FNAR cells. Cells were incubated with varying concentrations of taxol (A) and carboplatin (B) and LDA performed. Results are 3 separate experiments.



**Fig 4. Relative drug sensitivity of ALDH**<sup>high</sup> (red line) and ALDH<sup>low</sup> (blue line) FNAR cells. Cells were incubated with varying concentrations of (A) paclitaxel, (B) carboplatin, and (C) gemcitabine and LDA performed. Results are 3 separate experiments.

human ovarian cancer line are resistant to drugs commonly used in the treatment of ovarian cancer.

The two subpopulations from the FNAR lines have been transplanted intraperitoneally into female Lewis rats in three separate experiments. The results from the first experiment with the FNAR cells are available; the others are yet too early. All four rats transplanted with 50K unseparated FNAR cells died of overwhelming ovarian CA at a median of 177 days. Only one of

four rats receiving 50K ALDH<sup>low</sup> cells from the KnockOut medium died, at 100 days. All rats transplanted with 50K ALDH<sup>high</sup> cells grown in KnockOut medium died, at a medium of 200 days. These data are consistent with early, transient engraftment from the ALDH<sup>low</sup> cells, with later, but persistant and fatal engraftment from the ALDH<sup>high</sup> cells. We are currently performing similar experiments with the Taxol resistant SCOV3 cells grown in standard and knock-out medium, and the preliminary results parallel those with the FNAR cells. The ALDH<sup>high</sup> cells recapitulate the heterogeneity of the cell line grown in knock-our medium (Figure 2B), have a longer doubling time and grow in suspension, while while the ALDH<sup>low</sup> cells only generate ALDH<sup>low</sup> cells (Figure 2A). Similar experiments transplant experiment using NOD/SCID-IL2R $\gamma^{null}$  (NSG) mice have also been performed with the Taxol-resistant SCOV3 cells and the results pending.

We have also performed expression arrays on the two subpopulations from both cells lines. Table 1 shows a genes of interest in a comparison of the FNAR ALDH<sup>high</sup> and ALDH<sup>low</sup> cells Not surprisingly, ALDH1 is markedly upregulated in the ALDH<sup>high</sup> cells. In addition, the stem cell markers WT1 and CD47 are also upregulated. CD24 has also been reported to be downregulated in ovarian (Meng et al Clin Exp Metastasis, Epub ahead of print May 18, 2002) and breast cancer (Al-Haii et al Proc Natl Acad Sci USA 100:3983-3988, 2003) and we have previously showed that GPI-anchored proteins, like CD59, are down-regulated in cancer stem cells. Interestingly. CD44, which has been reported to be upregulated in ovarian and breast cancer, is significantly down-regulated in the FNAR ALDH<sup>high</sup>. The Wnt and Hedgehog (Hh) signaling pathways are also upregulated in the ALDH<sup>high</sup> cells. The Taxol-resistant SCOV3 ALDH<sup>high</sup> showed a similar expression pattern when compared to the SCOV3 ALDH<sup>low</sup> cells (Table 2).

Gene	Fold upregulated	p value
ALDH1A2	+39-fold	0.02
WT1	+4.5-fold	0.02
CD47	+2.1-fold	0.001
CD44	-16.7-fold	0.001
CD59	-3-fold	0.03
CD24	-1.8-fold	0.005

Table 1. Expression differences betweenthe ALDHHighFNAR cells, as compared toADLHADLH

Gene	Fold upregulated	p value
ALDH1A1	+33.7-fold	<0.001
Wt1	Not on array	NA
CD47	+1.83-fold	0.01
CD24	-11.5-fold	<0.001
AR	-2.6-fold	<0.001
MUC1	-2.8-fold	< 0.001

Table 2. Expression differences betweenthe ALDHthe ALDH<

To date, there are limited reports of growing primary ovarian cancer in immunodeficient mice. However, many ovarian cancer cell lines grow IP in immunodeficient mice, and the pattern of growth of other human cancers in immunodeficient mice tends to parallel that seen clinically. As detailed in the proposal, we have attempted to develop an immunodeficient mouse model for primary ovarian carcinoma. CD45<sup>+</sup> cells represent a high percentage of the cells present in the ascites in many if not most women, and there is some data these inflammatory cells might inhibit engraftment. Thus, we isolated the EPCAM<sup>+</sup>/CD45<sup>-</sup> cells from the malignant ascites of a woman with ovarian carcinoma, and injected 1 x  $10^5$  cells IP into 3 NOD/SCID mice irradiated with 200 cGy. All 3 mice developed malignant ascites and peritoneal studding with human ovarian cancer. These data form the basis of subsequent studies looking at engraftment with subsets of fresh, explanted tumor isolated by CSC phenotype

In summary, it appears that ALDH expression appears to isolate a population of cells from both the rat ovarian carcinoma model and a human ovarian cancer cell line that have characteristics of CSCs as others have recently suggested (Kryczek *et al Int J Cancer.* 130:29-39, 2012). These cells grow more slowly and in suspension, recapitulate the heterogeneity of the line, are relatively drug-resistant *in vitro*, and express stem cell markers. The second specific aim is to develop treatments that target ovarian CSCs, with the ultimate intent of moving

promising approaches into the clinic. This aim has just begun until the second year of the grant, and was delayed with the loss of the ALDH<sup>high</sup> subpopulation. With characterization of the ALDH<sup>high</sup> and ALDH<sup>low</sup> subpopulations, these experiments are about to begin. Our preliminary data in hematologic malignancies suggest that inhibitors or telomerase and Hedgehog signaling are prime candidate drug for targeting the ovarian CSCs.

#### **Key Research Accomplishments**

Initial characterization of putative ovarian CSCs in FNAR model and human ovarian cell lines.

Using specialized culture medium, ALDH<sup>high</sup> sublines for both the FNAR rat model and the SCOV-3 human ovarian CA have been developed and are facilitating our characterization of the putative ovarian CSCs.

Preliminary data that the ALDH<sup>high</sup> sublines are phenotypically and functionally CSCs.

#### **Reportable Outcomes**

Sharrow AC, Ronnett BM, Thoburn CT, Barber JB, Giuntoli RL, Armstrong DK, Jones RJ, Hess AD. Identification and characterization of a spontaneous ovarian carcinoma in Lewis rats. J Ovarian Res. 3:9, 2010

Sharrow A, Ghiaur G, Gerber, Jones RJ. Cancer Stem Cell Principles. In, Translational Cancer Research: Molecular Therapeutics (Eds, Anderson, K and Kurzrock) Wiley, Hoboken, NJ, 2013 In Press.

# Personnel

Jones, Richard, PI (1.2 calendar months)

Hess, Allan, Co-Investigator (.60 calendar months)

Giuntoli, Robert, Co-Investigator (.60 calendar months)

Sharrow, Allison, Graduate Student (12 calendar months)

Rogers, Ophelia, Research Specialist (1.8 calendar months)

# Conclusion

We have developed culture conditions – primarily with the use of the serum-free KnockOut medium developed for growing undifferentiated ES cells – that permit large scale propagation of the putative ovarian CSCs in both rat and human cell lines. These putative CSCs phenotypically and biologically function as ovarian CSCs. The potential existence of ovarian CSCs has enormous clinical implications. Not only it would explain the transient remissions that characterize current treatments for ovarian carcinoma, but isolation and characterization of these cells will also facilitate the development of novel treatment approaches. Preliminary experiments suggest that ALDH<sup>high</sup> cells from fresh explanted ovarian cancer from ascites also appear to have CSC characteristics and may grow in NSG transplants are. Investigations into clinically-translatable treatments that target ovarian CSCs are underway.